Texas is currently home to 4888 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
Recruiting
This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
12/18/2024
Locations: Baylor College of Medicine- McNair Campus, Houston, Texas
Conditions: ENDOMETRIAL CANCER
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Recruiting
This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of ifinatamab deruxtecan (I-DXd). * Dose Expansion Part: To investigate the safety, tolerability and antitumor activ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: MDACC (MD Anderson Cancer Center), Houston, Texas
Conditions: Advanced Solid Tumor, Malignant Solid Tumor
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Recruiting
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: MD Anderson Cancer Center, Huston, Texas
Conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
National Adaptive Trial for PTSD Related Insomnia
Recruiting
Many Veterans with posttraumatic stress disorder (PTSD) have trouble sleeping or have frequent nightmares. So far, no medication has been approved for treatment of insomnia in PTSD. The purpose of this research study is to find out if taking medications called trazodone or eszopiclone can help decrease symptoms of insomnia in patients with PTSD. PTSD is a form of intense anxiety which sometimes results from severe trauma. Symptoms may include nightmares, flashbacks, troublesome memories, difficu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/18/2024
Locations: VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas
Conditions: Insomnia
Safety and Durability of Sirolimus for Treatment of LAM
Recruiting
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Lymphangioleiomyomatosis
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
Recruiting
Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysi... Read More
Gender:
ALL
Ages:
Between 25 years and 74 years
Trial Updated:
12/17/2024
Locations: University Hospital Dialysis Medical Center (DMC), San Antonio, Texas
Conditions: End Stage Renal Disease, Fatigue
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Recruiting
The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Recruiting
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
Recruiting
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/17/2024
Locations: San Antonio Military Medical Center (SAMMC), San Antonio, Texas
Conditions: Peripheral Nerve Injuries
Behavioral Insomnia Treatment in Mild Traumatic Brain Injury
Recruiting
This is a single site, two-armed random controlled trials (RCT) comparing six sessions of Cognitive Behavioral Therapy for Insomnia (CBT-I) with four sessions of Brief Behavioral Therapy for Insomnia (BBT-I) in service members with comorbid insomnia and prolonged postconcussive symptoms present for at least 3 months after Mild Traumatic Brain Injury (mTBI).
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
12/16/2024
Locations: Carl R. Darnall Army Medical Center, Fort Cavazos, Texas
Conditions: Insomnia, Mild Traumatic Brain Injury
Telephone Support in Advanced Gastrointestinal Cancer
Recruiting
The goal of this clinical trial is to see if telephone support programs help patients and their family caregivers adjust to advanced gastrointestinal cancer. A new telephone counseling program that involves practicing strategies for managing stress and symptoms will be compared to a telephone program involving education on quality-of-life issues and psychosocial support. The main questions it aims to answer are: Does our telephone counseling program lower the negative impact of patients' fatigu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Gastrointestinal Neoplasm Malignant, Caregiver Burden
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Recruiting
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: MD Anderson Cancer Center-University of Texas, Houston, Texas
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer